- Information Center
- Investment News
South Korea’s biotechnology firm Sillajen, Inc., has teamed up with U.S.-based Regeneron Pharmaceuticals Inc. to co-develop a treatment for kidney cancer.
The drug maker said in a regulatory filing Monday it has signed a deal with Regeneron to test out combination of its oncolytic virus vaccine Pexa-Vec with the U.S. firm’s immune checkpoint inhibitor REGN 2810 in combating renal cell carcinoma.
Under the deal, the two will run a phase 1 clinical trial tests on patients with kidney cancer with the drug cocktail or REGN 2810.
Pexa-Vec is an oncolytic virus vaccine designed to kill cancer cells using the body’s immune system after the patient’s cancer cells are infected with gene-manipulated vaccinia virus. Pexa-Vec infects cancer cells first, and then the patient’s immune system recognizes the infected cancer cells as foreign bodies and attacks them, explained the company.
Regeneron’s REGN-2810 is a programmed cell death protein 1 (PD-1) inhibitor that is being jointly developed by Sanofi and Regeneron.
Shares of Sillajen on Monday rose 1.32 percent to 11,500 won ($10.16) from the previous session.
By Shin Chan-ok
Copyrights Pulse by Maeil Business News Korea. All Rights Reserved.
Source: Pulse by Maeil Business News Korea (May. 8, 2017)